Search for dissertations about: "thesis in hepatitis c"

Showing result 16 - 20 of 125 swedish dissertations containing the words thesis in hepatitis c.

2. 16. On the outcome of antiviral therapy for hepatitis C virus genotype 2 or 3 infection

   Author : Åsa Alsiö; Göteborgs universitet; []
   Keywords : infectious diseases; virology; hepatitis c; treatment;

   Abstract : Abstract Approximately 80% of patients infected with HCV genotypes 2 or 3 achieve a sustained virological response (SVR), following 24 weeks of therapy with ribavirin and pegylated interferon (peg-IFN), but in light of considerable side effects and cost, shortened treatment duration without impaired efficacy is desirable. Thus, 382 genotype 2/3 infected patients were randomized in an investigator-initiated phase III study (NORDynamIC) evaluating the efficacy of 12 (short-term) vs. READ MORE

4. 17. Design and Synthesis of Hepatitis C Virus NS3 Protease Inhibitors : Targeting Different Genotypes and Drug-Resistant Variants

   Author : Anna Karin Belfrage; Anja Sandström; Ulf Ellervik; Uppsala universitet; []
   Keywords : NATURVETENSKAP; NATURAL SCIENCES; NATURVETENSKAP; NATURAL SCIENCES; hepatitis C virus; HCV; NS3 protease inhibitors; structure-activity relationship; 2 1H -pyrazinone; quinazoline; resistance; Pd catalysis; Medicinal Chemistry; Läkemedelskemi; Farmaceutisk vetenskap; Pharmaceutical Science;

   Abstract : Since the first approved hepatitis C virus (HCV) NS3 protease inhibitors in 2011, numerous direct acting antivirals (DAAs) have reached late stages of clinical trials. Today, several combination therapies, based on different DAAs, with or without the need of pegylated interferon-α injection, are available for chronic HCV infections. READ MORE

5. 18. Hepatitis C virus kinetics during antiviral treatment

   Author : Tony Carlsson; Karolinska Institutet; Karolinska Institutet; []
   Keywords : Hepatitis C virus RNA; genotype; kinetics; interferon-alpha; ribavirin.;

   Abstract : It is estimated that 170 million individuals have chronic hepatitis C virus (HCV) infection, whereof 20-30% will develop end stage liver disease within 20-30 years. Antiviral therapy can stop this deterioration and clear the infection in 40-80% of the patients depending on treatment and HCV genotype. READ MORE

6. 19. Kinetic studies of NS3 and NS5B from Hepatitis C virus : Implications and applications for drug discovery

   Author : Göran Dahl; Helena Danielson; Raffaele De Francesco; Uppsala universitet; []
   Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Hepatitis C virus; NS3; NS5B; enzyme kinetics; inhibition; resistance; drug; Biochemistry; Biokemi; Biokemi; Biochemistry;

   Abstract : The aim of these studies was to increase our understanding of the non-structural proteins 3 and 5B (NS3 and NS5B) from the hepatitis C virus (HCV), and thereby contribute to the development of new and better drugs against HCV.By studying NS3 with substitutions identified to be associated with resistance to NS3 inhibitors in clinical trials (R155Q, A156T and D168V) it was found that not all inhibitors were affected, indicating that cross-resistance can be avoided. READ MORE

7. 20. Peptidomimetic Enzyme Inhibitors : Targeting M. tuberculosis Ribonucleotide Reductase and Hepatitis C Virus NS3 Protease

   Author : Johanna Nurbo; Anders Hallberg; Anders Karlén; Anja Sandström; Per Arvidsson; Uppsala universitet; []
   Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; enzyme inhibitor; peptidomimetics; structure-activity relationship; tuberculosis; ribonucleotide reductase; hepatitis C virus; NS3 protease; Pharmaceutical chemistry; Farmaceutisk kemi; Medicinal Chemistry; Läkemedelskemi;

   Abstract : This thesis focuses on the design and synthesis of inhibitors targeting Mycobacterium tuberculosis ribonucleotide reductase (RNR) and hepatitis C virus (HCV) NS3 protease; enzymes that have been identified as potential drug targets for the treatment of tuberculosis and hepatitis C, respectively. Small peptides have been recognized as inhibitors of these enzymes. READ MORE